Ocugen at Chardan's Genetic Medicines Conference
Ocugen, Inc. (NASDAQ: OCGN), an innovative biotechnology firm, is making significant progress in gene and cell therapies. The company recently announced an in-person fireside chat featuring Dr. Arun Upadhyay, their Chief Scientific Officer and Head of Research & Development. This informative discussion is set to take place at Chardan’s 8th Annual Genetic Medicines Conference, reflecting Ocugen's commitment to advancing medical science.
Conference and Presentation Details
The fireside chat will occur in New York City. Dr. Upadhyay is looking forward to sharing insights about Ocugen's unique approaches to treating retinal diseases through their modifier gene therapy platform. This highlights not just Ocugen's potential but also its dedication to tackling critical health challenges faced by patients worldwide.
Dr. Upadhyay expressed, “I am excited to share information about Ocugen’s groundbreaking modifier gene therapy approach for retinal diseases as well as our ongoing clinical trials for retinitis pigmentosa, geographic atrophy, and Stargardt disease.” These discussions are essential for forging connections with the investor community and promoting Ocugen's mission among key stakeholders.
Perspectives from Ocugen's Leadership
In addition to Dr. Upadhyay’s presentation, members of Ocugen’s executive team will be available for one-on-one meetings with attendees. These interactions promise to offer valuable insights into the company's business and clinical development strategies, emphasizing Ocugen’s commitment to delivering innovative solutions that meet urgent medical needs.
Event Information
If you're interested in attending, here are the details for the fireside chat:
- Date: September 30, 2024
- Time: 10:30 a.m. ET
- Location: Westin Grand Central, New York, NY
Ocugen's Patient-Centered Approach
Ocugen, Inc. is passionate about the transformative potential of biotechnology. The company is dedicated to discovering and developing cutting-edge therapies that can enhance health outcomes significantly. Their innovative modifier gene therapy platform shows promise for treating a range of retinal diseases, potentially offering a single treatment option that addresses multiple conditions, thereby setting new standards in patient care.
Furthermore, Ocugen is also researching infectious diseases and orthopedic conditions to meet unmet medical needs. Their drive for innovation is backed by a strong research and development framework that employs advanced science and technology.
Connecting with Ocugen
To keep up with Ocugen's latest developments and innovative work, you can visit their official website and follow them on social media. Their dedication to health innovation is evident in their ongoing commitment to sharing progress and engaging with the community.
About Ocugen, Inc.
Ocugen, Inc. is focused on improving health and offering hope through innovative therapies for patients. Their emphasis on creating and commercializing gene therapies and vaccines places them at the forefront of medical advances.
If you have any questions or need more information, please contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com
Frequently Asked Questions
What is Ocugen's goal for attending the conference?
Ocugen intends to showcase its innovative modifier gene therapy for retinal diseases and connect with the investment community.
When will the fireside chat be held?
The fireside chat is scheduled for September 30, 2024, at 10:30 a.m. ET.
Who will host the fireside chat?
Dr. Arun Upadhyay, Ocugen's Chief Scientific Officer, will host the fireside chat.
What retinal diseases are targeted by Ocugen's therapies?
Ocugen focuses on treating retinal conditions such as retinitis pigmentosa, geographic atrophy, and Stargardt disease.
How can interested parties find more information about Ocugen?
Interested parties can visit Ocugen’s official website and follow their social media for updates and additional information.
